- Home
- CABR vs CRIS Comparison
CABR vs CRIS Comparison
Compare CABR & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABR | CRIS |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 12.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CABR | CRIS |
|---|---|---|
| Price | $1.03 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 58.2K | ★ 195.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $0.71 | $0.77 |
| 52 Week High | $1.65 | $3.18 |
Technical Indicators
Market Signals| Indicator | CABR | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 49.77 |
| Support Level | $0.78 | $0.80 |
| Resistance Level | $1.09 | $1.21 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 92.64 | 34.62 |
Price Performance
Historical ComparisonAbout CABR Caring Brands Inc.
Caring Brands Inc is a consumer wellness company that supports health and wellness through research and development. Its product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. The majority of revenue is generated from the sale of OTC and consumer products, as well as licensing royalties.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.